Originally reported by menafn. Read more
Archive summary Clinical & research
Biomednewsbreaks - Nrx Pharmaceuticals, Inc. (NASDAQ: NRXP) Receives FDA Feedback On Bioequivalence For Ketamine Product
NRx Pharmaceuticals (NASDAQ: NRXP) announced it received a letter from the FDA's Bioequivalence Program stating no bioequivalence deficiencies were identified at ...
Newsletter
The weekly digest
Weekly digest of US behavioral health policy and regulation, source-linked and practitioner-edited. Free; unsubscribe in one click.